Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2025)

Nuvalent's (NUVL) quarterly Other Non-Current Liabilities came in at $35000.0 in Q4 2025, down 75.0% on a QoQ basis from $140000.0 in Q3 2025.

Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends

Nuvalent (NUVL) has 2 years of Other Non-Current Liabilities data on file, last reported at $35000.0 in Q4 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $35000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35000.0 (changed N/A YoY) and the FY2025 annual result came in at $35000.0, changed N/A from the prior year.
Other Non-Current Liabilities fell to $35000.0 in Q4 2025, from $140000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $16.6 million in Q3 2024 to a low of $35000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Nuvalent	9.10 Bn	9.10 Bn	-

Download Data